Literature DB >> 9089711

In vivo biodistribution of [N-11C-methyl]KF 17837 using 3-D-PET: evaluation as a ligand for the study of adenosine A2A receptors.

S Stone-Elander1, J O Thorell, L Eriksson, B B Fredholm, M Ingvar.   

Abstract

(KF 17837, (E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine, was 11C-labelled by methylation at N-7 of the nor-compound, KF 17440, using [11C]methyl iodide. Radiochemical conversions of 50% or 70-80% were obtained using sodium hydride or potassium carbonate, respectively, as base. Total synthesis time was 40-45 min, including isolation by semipreparative liquid chromatography. Cerebral uptake of [N-11C-methyl]KF 17837 in Cynomolgus monkeys, evaluated using positron emission tomography (PET), was so low that regional differences in distribution kinetics were revealed first after increasing injected dose 3-fold and using 3-D mode of data acquisition. At all times, the relative regional retention (maximum striatum:cerebellum: cortex approximately 1.1:1:0.8 at 20 min) was considerably different from the known relative density of A2A receptors in these regions. Radioactivity decreased more rapidly in the cortex than in the striatum and cerebellum (by 20% vs. 3-7%, respectively, between 5 and 50 min). Addition of carrier to [N-11C-methyl]KF 17837 only marginally affected the cerebral radiotracer uptake. By contrast, in the heart the initial tracer uptake was high and the elimination kinetics was enhanced by adding unlabelled carrier. We have thus shown that KF 17837 passes the blood-brain barrier, though to a very low extent. This fact and the apparently high nonspecific binding in vivo of [N-11C-methyl]KF 17837 in regions with low receptor densities limits its usefulness as a ligand for quantification of the adenosine A2A receptors in the primate brain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9089711     DOI: 10.1016/s0969-8051(96)00216-8

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  4 in total

1.  Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists.

Authors:  Charles W Schindler; Marzena Karcz-Kubicha; Eric B Thorndike; Christa E Müller; Srihari R Tella; Sergi Ferré; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

Review 2.  In Vivo Positron Emission Tomography Imaging of Adenosine A2A Receptors.

Authors:  Meng-Juan Sun; Fang Liu; Ya-Fei Zhao; Xiao-Ai Wu
Journal:  Front Pharmacol       Date:  2020-11-26       Impact factor: 5.810

Review 3.  Allosteric Interactions between Adenosine A2A and Dopamine D2 Receptors in Heteromeric Complexes: Biochemical and Pharmacological Characteristics, and Opportunities for PET Imaging.

Authors:  Kavya Prasad; Erik F J de Vries; Philip H Elsinga; Rudi A J O Dierckx; Aren van Waarde
Journal:  Int J Mol Sci       Date:  2021-02-09       Impact factor: 5.923

Review 4.  In Vivo PET Imaging of Adenosine 2A Receptors in Neuroinflammatory and Neurodegenerative Disease.

Authors:  Anna Vuorimaa; Eero Rissanen; Laura Airas
Journal:  Contrast Media Mol Imaging       Date:  2017-11-20       Impact factor: 3.161

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.